Stemline Therapeutics Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Stemline Therapeutics (STML) Misses Q1 EPS by 10c, Revenues Beat
May 10, 2019 6:36 AM EDTStemline Therapeutics (NASDAQ: STML) reported Q1 EPS of ($0.73), $0.10 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $5.05 million versus the consensus estimate of $2.36 million.
Since ELZONRIS became commercially available in January, we have been very pleased with the... More
